Cybeats Announces Date for First Quarter Fiscal 2026 Financial Results
MyFlyYatra Expanding San Francisco to India Flight Route for Travelers with Economy, Premium, Business and First-Class Travel
SpendLayer Announces Official Platform Launch on 28 May 2026
Backstageplay to Acquire Software, IP, and Databases from NeXT Sports Group
Paragon Advanced Labs Provides Corporate Update
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent…
Media Release COPENHAGEN, Denmark; December 11, 2022 Epcoritamab featured in multiple data disclosures, including four…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR…
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet…
Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC),…
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec….
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients…
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models…
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in…
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1…
“Austin Accident Lawyer” Andrew Traub shares how his firm has helped their clients get past…
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…